| 目录号 | MZ4001-500MG | 售价 | 680.00元 | ||||||||||||||||||||||||||||||||||||||||||||
| 规格 | 500mg | 运输温度 | 室温运输 | ||||||||||||||||||||||||||||||||||||||||||||
| 其他名称 | 保存温度 | 2-8℃干燥保存 | |||||||||||||||||||||||||||||||||||||||||||||
| CAS号 | 2353-33-5 | 有效期 | 或置于-20℃长期干燥保存，至少3年有效。 | ||||||||||||||||||||||||||||||||||||||||||||
| 应用 | 订购数量 |
|
|||||||||||||||||||||||||||||||||||||||||||||
|
产品简介: Decitabine (5-aza-2'-deoxycytidine) 地西他滨(5-氮杂-2′-脱氧胞苷)
产品信息
产品描述 地西他滨（Decitabine），又称为5-氮杂-2′-脱氧胞苷（5-Aza-2′-deoxycytidine），一种胞嘧啶类似物，一旦插入DNA后，可用作DNA甲基转移酶的一种自杀性底物。能抑制DNA甲基转移酶活性，引起DNA低甲基化和沉默基因的活化。地西他滨是一种化疗剂，可抑制人肿瘤细胞系的生长。还能去甲基分化相关基因。逆转胚胎干细胞分化。
产品特性 1） CAS NO：2353-33-5 2） 化学名：4-Amino-1-(2-deoxy-β-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one 3） 英文同义名：2'-Deoxy-5-azacytidine, 5-Aza-2'-deoxycytidine, Deoxycytidine, NSC 127716, 5AZA-CdR 4） 中文同义名：2'-脱氧-5-氮杂胞苷；5-氮杂-2′-脱氧胞苷；脱氧胞苷； 5） 分子式：C8H12N4O4 6） 分子量：228.21 7） 纯度：≥99%(HPLC) 8） 外观：白色或类白色结晶性粉末 9） 溶解性：溶于DMSO（~45 mg/ml），略溶于水（~10mg/ml），几乎不溶于乙醇
10） 化学结构图：
保存与运输方法 保存：2-8℃干燥保存，或置于-20℃长期干燥保存，至少3年有效。 运输：室温运输
注意事项 1） 地西他滨遇水会迅速降解，建议用有机溶剂如DMSO来配制母液，置于-20℃分装保存，至少3个月稳定。若需要用水或水溶性缓冲液来配制母液，请现配现用，且尽快用完，不建议做保存。 2） 本品本身并非完全无菌的，若需要无菌溶液且用水或水溶性缓冲液来溶解粉末，需过滤除菌后再使用。 3） 本品仅用作科研用途，不得用作临床诊断或治疗，不得用于食品或药品，绝对禁止用在人身上。 4） 为了您的安全和健康，请穿实验服并戴一次性手套操作。
配制储存液
|
|||||||||||||||||||||||||||||||||||||||||||||||
|
文献1，Maes K et al.The role of DNA damage and repair in decitabine-mediated apoptosis in multiple myeloma. Oncotarget. 2014 May 30;5(10):3115-29. PMID: 24833108 体外研究： 样本类型（Sample type）：Human myeloma cell lines (HMCLs)(OPM-2, NCI-H929, RPMI-8226 and JJN3 cells) 药物配制（Preparation）：Decitabine (Dacogen) was dissolved in dimethylsulfoxide. 实验方法（Assay）：HMCLs were treated with different concentrations of decitabine (DAC) for indicated timepoints. Apoptosis was determined by flow cytometry using AnnexinV-FITC/7'AAD staining. 实验结果（Results）：OPM-2 and NCI-H929 cells showed significant induction of apoptosis from 3 days on, while RPMI-8226 and JJN3 cells were more sensitive showing increased apoptosis already after 2 days. 体内研究： 动物模型（Animal Model）：5T33MM mice 药物配制（Preparation）：For in vivo experiments, decitabine was used as a filter sterilized 10% hydroxypropyl- cyclodextran suspension. 实验方法（Assay）：At day 0, naive C57BL/KaLwRij mice were intravenously injected with 5×1055T33MM cells. Mice were treated with decitabine starting at day 1 (intraperitoneal injection, 6 days/week). Treatment groups were vehicle (n=9), 0.2 (n=9) and 0.5mpk decitabine (n=9). Mice were sacrificed individually when showing signs of morbidity. 实验结果（Results）：Tumor load in the BM and serum M-spike were significantly lower for all decitabine treatment groups. 5T33MM mice treated with decitabine had significant higher survival rates when compared to vehicle treated mice: 29 and 36 days for respectively 0.2mg/kg decitabine and 0.5mg/kg decitabine versus 25 days for vehicles. |
|
文献2，Terse P et al. Subchronic oral toxicity study of decitabine in combination with tetrahydrouridine in CD-1 mice. Int J Toxicol. 2014 Mar-Apr;33(2):75-85. PMID: 24639139 体内研究： 动物模型（Animal Model）：CD-1 mice (male 30-38 g and female 24-31g) 药物配制（Preparation）：For Group 1 (DAC vehicle), a 5% solution of potassium phosphate buffer in sodium chloride for injection (SCFI) was prepared; for Groups 2 to 5, a 2 mg/mL stock solution of DAC was prepared by adding the appropriate amount of DAC to the potassium phosphate buffer; the pH was adjusted to 6.90 ± 2.90%). The dosing formulations of DAC (0.02, 0.04, and 0.1 mg/mL) were prepared by diluting the 2 mg/mL stock solution with SCFI. 实验方法（Assay）：Animals were gavaged with DAC or its vehicle 1 hour ± 5 minutes after administration of THU or its vehicle at a dose volume of 10 mL/kg. |
— —Written/Edited by V. Shallan【版权归MKBio懋康所有】
上海懋康生物科技有限公司是一家涉足于生命科学和生物技术领域研究的试剂、仪器和实验室消耗品与实验服务工作，主要从事细胞生物学、植物学、分子生物学、免疫学、生物化学、蛋白组学。生物制药与诊断试剂研发生产等领域。 本公司秉承“以人为本，以诚为信、合同守信”的经营理念。坚持"品质保障"的原则为广大客户提供优质产品。
